ERBB2 and breast cancer: Knuefermann et al (2003) reported that, in MCF7 breast cancer cells, overexpression of HER-2 caused a PI3K-dependent activation of AKT, and was associated with an increased resistance of cells to multiple chemotherapeutic agents.